Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,024,004 papers from all fields of science
Search
Sign In
Create Free Account
HMR 3647
Known as:
HMR-3647
, HMR3647
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
telithromycin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Ketolide agents HMR 3004 and HMR 3647 (telithromycin) inhibit the growth of Plasmodium falciparum in vitro.
M. Makgatho
,
Eric Maimela
,
F. Mbajiorgu
African Health Sciences
2016
Corpus ID: 13237802
BACKGROUND Malaria is on the increase due to emergence of parasite drug resistance and there is thus an urgent need for the…
Expand
Highly Cited
2002
Highly Cited
2002
Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci
V. Shortridge
,
P. Zhong
,
+5 authors
R. Flamm
Antimicrobial Agents and Chemotherapy
2002
Corpus ID: 23843894
ABSTRACT The activity of a new ketolide, ABT-773, was compared to the activity of the ketolide telithromycin (HMR-3647) against…
Expand
2001
2001
In Vivo Efficacy of Telithromycin (HMR3647) againstStreptococcus pneumoniae and Haemophilus influenzae
H. Okamoto
,
S. Miyazaki
,
K. Tateda
,
Y. Ishii
,
K. Yamaguchi
Antimicrobial Agents and Chemotherapy
2001
Corpus ID: 7057309
ABSTRACT The in vivo activity of telithromycin against erythromycin A- and penicillin G-resistant Streptococcus pneumoniae was…
Expand
Review
2001
Review
2001
Recent developments on ketolides and macrolides.
Yong-Jin Wu
,
W. Su
Current Medicinal Chemistry
2001
Corpus ID: 41992960
Recent semi-synthetic studies of erythromycin A culminated in the discovery of two ketolide drug candidates, HMR-3647 and ABT-773…
Expand
2001
2001
Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK.
A. Johnson
,
C. Henwood
,
L. Tysall
,
M. Warner
International Journal of Antimicrobial Agents
2001
Corpus ID: 35204537
Review
2001
Review
2001
Telithromycin. Aventis Pharma.
A. Johnson
Current opinion in investigational drugs
2001
Corpus ID: 42230976
The ketolide telithromycin (HMR-3647; Ketek), a derivative of clarithromycin, has been launched by Aventis Pharma (formerly…
Expand
2000
2000
In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniaein Japan
Toshiyuki Yamaguchi
,
Y. Hirakata
,
+6 authors
S. Kohno
Antimicrobial Agents and Chemotherapy
2000
Corpus ID: 33943169
ABSTRACT The in vitro activity of telithromycin (HMR3647), a new ketolide, against Mycoplasma pneumoniae was determined by the…
Expand
2000
2000
In Vitro Activities of the Ketolides Telithromycin (HMR 3647) and HMR 3004 Compared to Those of Clarithromycin against Slowly Growing Mycobacteria at pHs 6.8 and 7.4
Nalin Rastogi
,
K. S. Goh
,
M. Berchel
,
A. Bryskier
Antimicrobial Agents and Chemotherapy
2000
Corpus ID: 25190036
ABSTRACT The in vitro activities of HMR 3647 (telithromycin) and HMR 3004, two novel semisynthetic ketolides, were investigated…
Expand
Highly Cited
1999
Highly Cited
1999
The New Ketolide HMR3647 Accumulates in the Azurophil Granules of Human Polymorphonuclear Cells
Christine Miossec-Bartoli
,
L. Pilatre
,
+4 authors
A. Diu‐Hercend
Antimicrobial Agents and Chemotherapy
1999
Corpus ID: 10107491
ABSTRACT HMR3647 is a semisynthetic representative of a new group of drugs, the ketolides, derived from erythromycin A. Since…
Expand
1998
1998
In Vitro Activity of the New Ketolide HMR3647 in Comparison with Those of Macrolides and Pristinamycins againstEnterococcus spp
C. Torres
,
M. Zarazaga
,
+4 authors
F. Baquero
Antimicrobial Agents and Chemotherapy
1998
Corpus ID: 36172495
ABSTRACT Ninety-four erythromycin-susceptible and 107 erythromycin-resistant enterococcal strains (MIC of ≥512 μg/ml) were…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE